相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
Pharmacological and molecular docking studies reveal that glibenclamide competitively inhibits diazoxide-induced mitochondrial ATP-sensitive potassium channel activation and pharmacological preconditioning
Plinio Bezerra Palacio et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis
Jeong Yee et al.
CLINICAL THERAPEUTICS (2021)
Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype
Tanja Dujic et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Trends in Diabetes Treatment and Control in US Adults, 1999-2018
Michael Fang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETOLOGIA (2020)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2020 EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2020)
Drug-drug-gene interactions and adverse drug reactions
Mustafa Adnan Malki et al.
PHARMACOGENOMICS JOURNAL (2020)
Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives
Kamlesh Khunti et al.
DIABETES THERAPY (2020)
Latest Evidence on Sulfonylureas: What's New?
Lawrence A. Leiter
DIABETES THERAPY (2020)
Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Wendy K. Chung et al.
DIABETES CARE (2020)
Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel
Agostino Consoli et al.
DIABETES OBESITY & METABOLISM (2020)
Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes
Francesco Zaccardi et al.
DIABETES OBESITY & METABOLISM (2020)
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update
Lorraine Lipscombe et al.
CANADIAN JOURNAL OF DIABETES (2020)
Japanese Clinical Practice Guideline for Diabetes 2019
Eiichi Araki et al.
JOURNAL OF DIABETES INVESTIGATION (2020)
Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial
Wen-Huan Feng et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
Thomas A. Zelniker et al.
CIRCULATION (2019)
Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin
Priscilla Hollander et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
The characteristics and pattern of care for the type 2 diabetes mellitus population in the MENA region during Ramadan: An international prospective study (DAR-MENA T2DM)
Mohamed Hassanein et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Standards of medical care for type 2 diabetes in China 2019
Weiping Jia et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2019)
Diabetes: Is There a Future for Pharmacogenomics Guided Treatment?
Ewan R. Pearson
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride
Elisabetta Patorno et al.
DIABETES CARE (2019)
Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data
John M. Dennis et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Identification of an ATP-sensitive potassium channel in mitochondria
Angela Paggio et al.
NATURE (2019)
A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses
Alan Maloney et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?
Ruth L. M. Cordiner et al.
DIABETES OBESITY & METABOLISM (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
Julio Rosenstock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
Priscilla Hollander et al.
DIABETES THERAPY (2018)
Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
Priscilla Hollander et al.
DIABETES THERAPY (2018)
Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial
Martin Ridderstrale et al.
DIABETES OBESITY & METABOLISM (2018)
The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents
Stephen Colagiuri et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2018)
Do sulphonylureas still have a place in clinical practice?
Kamlesh Khunti et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study
Pamela Bowman et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables
Emma Ahlqvist et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
A Global Overview of Precision Medicine in Type 2 Diabetes
Hugo Fitipaldi et al.
DIABETES (2018)
Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data
John M. Dennis et al.
DIABETES CARE (2018)
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Aidin Rawshani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genetics of Monogenic Diabetes: Present Clinical Challenges
Shivani Misra et al.
CURRENT DIABETES REPORTS (2018)
Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10256 individuals from the United Kingdom and Germany
Kamlesh Khunti et al.
DIABETES OBESITY & METABOLISM (2018)
Long-term Trends in Antidiabetes Drug Usage in the US: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes
Olga Montvida et al.
DIABETES CARE (2018)
Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data
Steve Bain et al.
DIABETES OBESITY & METABOLISM (2017)
The University Group Diabetes Program 1961-1978: pioneering randomized controlled trial
Henry Blackburn et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2017)
Pharmacotherapy of treatment resistant' type 2 diabetes
Andre J. Scheen
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease
Wenhuan Feng et al.
JOURNAL OF DIABETES (2017)
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial
Olga Vaccaro et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events
Antonios Douros et al.
DIABETES CARE (2017)
Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease
Connor A. Emdin et al.
DIABETES (2017)
Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study
Jil Mamza et al.
ANNALS OF MEDICINE (2016)
The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials
Dimitris Varvaki Rados et al.
PLOS MEDICINE (2016)
Is gliclazide a sulfonylurea with difference? A review in 2016
Awadhesh Kumar Singh et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)
Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents
Siew Pheng Chan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Mortality risk among sulfonylureas: a systematic review and network meta-analysis
Scot H. Simpson et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It's Time to Move On!
Saul Genuth
DIABETES CARE (2015)
KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients
Qing Li et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2014)
Sulfonylureas: A New Look at Old Therapy
Peter M. Thule et al.
CURRENT DIABETES REPORTS (2014)
Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes
S. Zoungas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Safety and Efficacy of Gliclazide as Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Trials
Gijs W. D. Landman et al.
PLOS ONE (2014)
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
Martin Ridderstrale et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis
J. A. Hirst et al.
DIABETOLOGIA (2013)
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Association between TCF7L2 Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide
Martin Javorsky et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2013)
Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus A Cohort Study
Christianne L. Roumie et al.
ANNALS OF INTERNAL MEDICINE (2012)
Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study
S. R. Aravind et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Variations in tissue selectivity amongst insulin secretagogues: a systematic review
A. S. Abdelmoneim et al.
DIABETES OBESITY & METABOLISM (2012)
The Duration of Sulfonylurea Treatment Is Associated with β-Cell Dysfunction in Patients with Type 2 Diabetes Mellitus
Mi-Seon Shin et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2012)
Heterozygous ABCC8 mutations are a cause of MODY
P. Bowman et al.
DIABETOLOGIA (2012)
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
Baptist Gallwitz et al.
LANCET (2012)
Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A
Veronica Y. Lang et al.
PHARMACOGENETICS AND GENOMICS (2012)
The Molecular Genetics of Sulfonylurea Receptors in the Pathogenesis and Treatment of Insulin Secretory Disorders and Type 2 Diabetes
Veronica Lang et al.
CURRENT DIABETES REPORTS (2011)
The Cost-Effectiveness of Personalized Genetic Medicine The case of genetic testing in neonatal diabetes
Siri Atma W. Greeley et al.
DIABETES CARE (2011)
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin A randomized, 52-week, double-blind, active-controlled noninferiority trial
Michael A. Nauck et al.
DIABETES CARE (2011)
Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes
Z. Schroner et al.
DIABETES OBESITY & METABOLISM (2011)
The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial
S. Al Sifri et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Rosiglitazone Revisited An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality
Steven E. Nissen et al.
ARCHIVES OF INTERNAL MEDICINE (2010)
Loss-of-Function CYP2C9 Variants Improve Therapeutic Response to Sulfonylureas in Type 2 Diabetes: A Go-DARTS Study
K. Zhou et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al.
B. Gallwitz et al.
DIABETES OBESITY & METABOLISM (2010)
Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes
Olivia J. Phung et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease
Maureen F. Moen et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Intensive glucose control and macrovascular outcomes in type 2 diabetes
F. M. Turnbull et al.
DIABETOLOGIA (2009)
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William Duckworth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas
Georgia Ragia et al.
PHARMACOGENOMICS (2009)
The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel
Michael A. Burke et al.
CIRCULATION RESEARCH (2008)
Ser1369Ala Variant in Sulfonylurea Receptor Gene ABCC8 Is Associated With Antidiabetic Efficacy of Gliclazide in Chinese Type 2 Diabetic Patients
Yan Feng et al.
DIABETES CARE (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Chronic Antidiabetic Sulfonylureas In Vivo: Reversible Effects on Mouse Pancreatic β-Cells
Maria Sara Remedi et al.
PLOS MEDICINE (2008)
Testing the bipartite model of the sulfonylurea receptor binding site:: Binding of A-, B-, and A+B-site ligands
Marcus Winkler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Variation in TCF7L2 influences therapeutic response to sulfonylureas -: A GoDARTs study
Ewan R. Pearson et al.
DIABETES (2007)
Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes
Huijuan Zhang et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects
Yifan Zhang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
A systematic review and meta-analysis of hypoglycemia and cardiovascular event - A comparison of glyburide with other secretagogues and with insulin
Azim S. Gangji et al.
DIABETES CARE (2007)
Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the diabetes prevention program
Jose C. Florez et al.
DIABETES (2007)
Defining a binding pocket for sulfonylureas in ATP-sensitive potassium channels
Wanda H. Vila-Carriles et al.
FASEB JOURNAL (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Ewan R. Pearson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effects of gliclazide dose escalation on postprandial hyperglycemia in type 2 diabetes mellitus: A prospective, open-label, case-controlled, dose-escalation study
Poobalan Naidoo et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2006)
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
SFA Grant et al.
NATURE GENETICS (2006)
Secondary sulfonylurea failure: Comparison of period until insulin treatment between diabetic patients treated with gliclazide and glibenclamide
J Satoh et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2005)
Mechanisms of β-cell death in type 2 diabetes
MY Donath et al.
DIABETES (2005)
Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4α mutations in a large European collection
ER Pearson et al.
DIABETOLOGIA (2005)
Sulfonylurea induced beta-cell apoptosis in cultured human islets
K Maedler et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide
HL Maddock et al.
CARDIOVASCULAR DRUGS AND THERAPY (2004)
The UGDP controversy - thirty-four years of contentious ambiguity laid to rest
TB Schwartz et al.
PERSPECTIVES IN BIOLOGY AND MEDICINE (2004)
GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients
G Schernthaner et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
Genetic cause of hyperglycaemia and response to treatment in diabetes
ER Pearson et al.
LANCET (2003)
Sulphonylurea action revisited - the post-cloning era
FM Gribble et al.
DIABETOLOGIA (2003)
Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications
JP Riveline et al.
DIABETES & METABOLISM (2003)
Association of hypoglycemia and cardiac ischemia - A study based on continuous monitoring
C Desouza et al.
DIABETES CARE (2003)
Differential selectivity of insulin secretagogues - Mechanisms, clinical implications, and drug interactions
FM Gribble et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2003)
Sulfonylurea stimulation of insulin secretion
P Proks et al.
DIABETES (2002)
ATP-sensitive potassium channels participate in glucose uptake in skeletal muscle and adipose tissue
T Miki et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2002)
Pharmacokinetics and pharmacodynamics of extended-release glipizide GITS compared with immediate-release glipizide in patients with type II diabetes mellitus
M Chung et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Disruption of Sur2-containing KATP channels enhances insulin-stimulated glucose uptake in skeletal muscle
WA Chutkow et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells
CL Lawrence et al.
DIABETOLOGIA (2001)
Glimepiride block of cloned ß-cell, cardiac and smooth muscle KATP channels
DK Song et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
分享论文
